Chinook Therapeutics downgraded by Wedbush with a new price target
$KDNY
Biotechnology: Pharmaceutical Preparations
Health Care
Wedbush downgraded Chinook Therapeutics from Outperform to Neutral and set a new price target of $42.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 8/8/2023 | $42.00 | Outperform → Neutral | Wedbush |
| 3/6/2023 | $41.00 | Overweight | Piper Sandler |
| 3/1/2023 | $43.00 | Buy | Guggenheim |
| 12/5/2022 | $30.00 | Overweight | Wells Fargo |
| 6/28/2022 | $30.00 | Buy | Stifel |